To note, following current standard therapy, when oral temozolomide is combined with radiation therapy, according to MGMT status, the median overall survival of brain tumor patients ranges from 9 to 13.5 months60,61 and consistently translates into, a significant but unimpressive overall survival of 3457 or 3662 days with no long term survival, when tested in the animal model employed in this study. Here, MGMT is linked to brain neoplasm.